Download the Case Study
Accelerating Enrollment in a Competitive Ulcerative Colitis Landscape
Accelerating Enrollment in a Competitive Ulcerative Colitis Landscape
Accelerating Enrollment in a Competitive Ulcerative Colitis Landscape
Clinical trials in ulcerative colitis (UC) are increasingly complex and competitive. High screen failure rates driven by central endoscopy requirements, along with operational challenges such as stool sample collection, can significantly impact enrollment timelines and overall study execution.
The following case study highlights how Medpace successfully navigated these challenges in an early, placebo-controlled UC study.
Your Next Breakthrough Starts Here
Leading GI & Hepatology CRO
Medpace offers deep therapeutic expertise and global operational experience in managing clinical trials for inflammatory bowel disease (IBD), including both Crohn’s disease and ulcerative colitis. We understand the unique challenges of IBD trials, including recruitment and retention and the need for centralized endoscopy and histopathology review. Our understanding of these complex conditions helps us position our Sponsors for success. In fact, our in-house experts pioneered award-winning work that is validated and internationally recognized in the standardization of centrally reviewed endoscopy for inflammatory bowel disease research. Combined with our proven processes and global site relationships, Sponsors can overcome these hurdles and advance their IBD therapies with confidence.
